Group 1 - The Hong Kong Innovative Drug ETF (513120) has seen a year-to-date increase of over 57% as of June 30, 2025, making it one of the top performers in its category [1] - The ETF's latest scale reached 13.425 billion, ranking it first among all pharmaceutical ETFs in the market [1] - The ETF has experienced net inflows in 4 out of the last 5 trading days, totaling 805 million [1] Group 2 - The CSI Hong Kong Innovative Drug Index (931787) has its top ten weighted stocks accounting for 67.94%, including companies like Innovent Biologics and WuXi Biologics [2] - The National Healthcare Security Administration will hold a press conference on July 1 to discuss measures supporting the high-quality development of innovative drugs, emphasizing the use of healthcare data for drug research [2] Group 3 - CITIC Securities remains optimistic about the pharmaceutical industry in the second half of 2025, focusing on innovation and the global competitiveness of Chinese pharmaceutical companies [3] - The Hong Kong Innovative Drug ETF closely tracks the CSI Hong Kong Innovative Drug Index, covering leading stocks in the sector and allowing T+0 trading for enhanced liquidity [3]
近一月日均成交医药类居首！港股创新药ETF(513120)年初至今累计上涨超57%，近5日“吸金”超8亿元
Sou Hu Cai Jing·2025-07-01 02:17